BACKGROUND: Vascular endothelial growth factor (VEGF), which affects tumor angiogenesis, is expressed as different splice variants, including the major isoforms VEGF165and VEGF121, and can be cleaved by plasmin to generate VEGF110. The amount of VEGF121and VEGF110in biological samples has not been well studied. METHODS: We developed an ELISA that detects VEGF165and VEGF121equally, but does not detect VEGF110. We used this ELISA together with 2 other ELISAs, one detecting VEGF165and the other detecting VEGF165, VEGF121, and VEGF110equally, to assess the concentrations of VEGF121and VEGF110in ovarian cancer tumors. RESULTS: The median concentrations in ovarian cancer tumor lysates were 0.61 (range <0.055-74) fmol/mg protein for VEGF165, 1.4 (range <0.20 -500) fmol/mg protein for VEGF165plus VEGF121, and 2.3 (range <0.079 -520) fmol/mg protein for total VEGF including VEGF110(n = 248). VEGF concentrations measured by the 3 ELISAs were highly correlated (r = 0.91-0.94). Median estimated VEGF121and VEGF110concentrations were 0.77 and 0.58 fmol/mg protein, respectively. In lysates with measurable VEGF165and total VEGF concentrations, mean VEGF165was approximately 31% (SD 23%) of the total VEGF (n = 217). In contrast, VEGF165constituted approximately half of the total circulating VEGF. CONCLUSION: VEGF165, VEGF121, and VEGF110may be present at significant amounts in ovarian cancer tumors.
Gutierrez, J., Konecny, G. E., Hong, K., Burges, A., Henry, T. D., Lambiase, P. D., … Meng, Y. G. (2008). A new ELISA for use in a 3-ELISA system to assess concentrations of VEGF splice variants and VEGF110 in ovarian cancer tumors. Clinical Chemistry, 54(3), 597–601. https://doi.org/10.1373/clinchem.2007.096099